Pulmonx Target of Unusually Large Options Trading (NASDAQ:LUNG)

Pulmonx Corporation (NASDAQ:LUNG) was the recipient of unusually large options trading activity on Thursday. Investors bought 3,491 put options on the stock. This represents an increase of approximately 1,895% compared to the average volume of 175 put options.

Analyst Ratings Changes

A number of research firms have weighed in on LUNG. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a report on Monday, July 13th. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pulmonx has a consensus rating of “Moderate Buy” and a consensus price target of $7.67.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Banco BTG Pactual S.A. acquired a new stake in Pulmonx during the fourth quarter worth about $102,000. Squarepoint Ops LLC acquired a new position in Pulmonx in the 4th quarter valued at approximately $91,000. Two Sigma Investments LP lifted its position in shares of Pulmonx by 50.3% in the 3rd quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock worth $75,000 after acquiring an additional 15,557 shares during the period. Jain Global LLC lifted its position in shares of Pulmonx by 62.9% in the 4th quarter. Jain Global LLC now owns 30,566 shares of the company’s stock worth $68,000 after acquiring an additional 11,800 shares during the period. Finally, Opal Capital LLC acquired a new stake in shares of Pulmonx during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Trading Up 1.2%

Shares of Pulmonx stock opened at $1.63 on Friday. Pulmonx has a 1 year low of $1.13 and a 1 year high of $2.89. The company’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $1.47. The company has a market cap of $68.85 million, a price-to-earnings ratio of -1.41 and a beta of 0.30. The company has a current ratio of 4.91, a quick ratio of 4.04 and a debt-to-equity ratio of 0.81.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 90.27%. The firm had revenue of $22.76 million during the quarter, compared to analysts’ expectations of $22.39 million. As a group, sell-side analysts expect that Pulmonx will post -1.13 EPS for the current year.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.